TORONTO, July 11 /CNW/ - Spectral Diagnostics Inc. ("Spectral"), today
announced the commercial placement of their proprietary sepsis assay system
("EAA(TM)") in two of Italy's largest hospitals though Estor S.p.A. ("Estor"),
a major distributor of medical products in Italy. These systems measure
circulating Endotoxin in patients and give accurate results in less than 30
minutes, enabling rapid initiation of appropriate treatment, and monitoring of
its effectiveness.
Estor was established on May 1, 1999 as a spin-off of the Hospital Supply
Division of Aventis (ex-Hoechst). The sales team has been operating in the
fields of Dialysis since 1980, Interventional Cardiology since 1990 and ICU
from 1999, distributing unique and innovative products such as Toray PMMA
based dialysers, and the Toray Endotoxin absorption cartridge ("Toraymyxin").
"We are very pleased to see this uptake of the EAA(TM). Estor is an
experienced and knowledgeable distributor of products, using a 'theranostics
approach', aimed at reducing the impact of sepsis," stated Dr. Paul Walker,
President & CEO of Spectral. "This early adoption of equipment and tests for
the EAA(TM) in Italy should lead to increased revenue in the latter part of
our current fiscal year." added Dr. Walker.
"Estor has been engaged in the promotion of Toraymyxin, the cartridge for
extracorporeal removal of Endotoxin, for more than 4 years treating more than
1000 patients in Italy. We now have the appropriate diagnostic tool for
detecting Endotoxemia and properly selecting patients for the use of
Toraymyxin. We strongly believe that the association between EAA(TM) and
Toraymyxin could represent a revolution in the management of septic shock,"
commented Dr. Federico D'Avanzo, President of Estor.
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products include Spectral's rapid West Nile Virus assay and its FDA
approved rapid diagnostic for sepsis, the EAA(TM), as well as a range of other
biological reagents. Spectral's common shares are listed on The Toronto Stock
Exchange: SDI.
Information in this news release that is not current or historically
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, the future outlook
of Spectral and anticipated events or results are assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected.
%SEDAR: 00002006E
